Existing therapies for Sézary syndrome (SS) are limited in efficacy and in disease control, and patients have very poor prognosis. Here, we report a case report of a patient who has a 16-year history of SS and related treatments (both standard and experimental). In particular, two drugs, one conventional (gemcitabine) and one experimental (mogamulizumab), were able to induce long lasting response. Patient refused to undergo allogeneic stem cell transplantation. After eleven lines of therapeutic approaches, the patient is in very good partial response and free of therapy at the latest available follow-up.

Nanni, L., Morigi, A., Casadei, B., Broccoli, A., Stefoni, V., Argnani, L., et al. (2019). A case report of the long treatment experience of a Sézary syndrome responder patient: 16 years through all the systemic and innovative therapies. HEMATOLOGICAL ONCOLOGY, 37(2), 202-204 [10.1002/hon.2573].

A case report of the long treatment experience of a Sézary syndrome responder patient: 16 years through all the systemic and innovative therapies

Nanni, Laura;Morigi, Alice;Casadei, Beatrice;Broccoli, Alessandro;Stefoni, Vittorio;Argnani, Lisa;Cavo, Michele;Zinzani, Pier Luigi
2019

Abstract

Existing therapies for Sézary syndrome (SS) are limited in efficacy and in disease control, and patients have very poor prognosis. Here, we report a case report of a patient who has a 16-year history of SS and related treatments (both standard and experimental). In particular, two drugs, one conventional (gemcitabine) and one experimental (mogamulizumab), were able to induce long lasting response. Patient refused to undergo allogeneic stem cell transplantation. After eleven lines of therapeutic approaches, the patient is in very good partial response and free of therapy at the latest available follow-up.
2019
Nanni, L., Morigi, A., Casadei, B., Broccoli, A., Stefoni, V., Argnani, L., et al. (2019). A case report of the long treatment experience of a Sézary syndrome responder patient: 16 years through all the systemic and innovative therapies. HEMATOLOGICAL ONCOLOGY, 37(2), 202-204 [10.1002/hon.2573].
Nanni, Laura; Morigi, Alice; Casadei, Beatrice; Broccoli, Alessandro; Stefoni, Vittorio; Argnani, Lisa; Cavo, Michele; Zinzani, Pier Luigi
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/732384
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact